NYSE: $ABBV
Breaking News in Dermatology
AbbVie has recently shared promising topline results from their Phase 3 INTREPID trial, which evaluated the efficacy and safety of lutikizumab in patients living with moderate to severe hidradenitis suppurativa (HS).
What the Trial Results Show
The study marks a significant milestone for patients who have previously been treated with biologic therapies but did not see adequate results. Lutikizumab, an investigational dual-variable domain interleukin-1? and 1? antagonist, showed statistically significant improvements compared to a placebo.
Key highlights from the study include:
- Patients treated with lutikizumab achieved significantly higher HiSCR50 (Hidradenitis Suppurativa Clinical Response) at week 16.
- The trial met its primary endpoint in patients who had previously failed to respond to prior biologic therapies.
- Safety profiles observed during the trial were generally consistent with those seen in previous studies of the drug.
Why This Matters
Hidradenitis suppurativa is a chronic, painful, and often debilitating inflammatory skin condition. For many patients, standard treatments are not enough to manage their symptoms. AbbVie’s data suggests that lutikizumab could provide a vital new mechanism of action for those battling this complex disease.
The company plans to further analyze these data and discuss the results with regulatory authorities, bringing the medical community one step closer to a new potential standard of care.
Source: Read More